Clinical Trial Update: A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Ipsen is conducting a Phase 1/2 clinical trial to evaluate IPN01195 as a single-agent therapy in adults with advanced solid tumors; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IPN01195

Snippet

Sponsor: Ipsen | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING